Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
about
Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advancesThe Evolution of T-cell Therapies for Solid MalignanciesPreventing stem cell transplantation-associated viral infections using T-cell therapyT-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effectT lymphocytes targeting native receptorsCurrent translational and clinical practices in hematopoietic cell and gene therapyAntiviral T-cell therapyToxicity and management in CAR T-cell therapyAdoptive immunotherapy for primary immunodeficiency disorders with virus-specific T lymphocytesIncreased β-haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases.Reversal of tumor immune inhibition using a chimeric cytokine receptor.Engineered T cells for cancer treatmentToward a Rapid Production of Multivirus-Specific T Cells Targeting BKV, Adenovirus, CMV, and EBV from Umbilical Cord Blood.Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanomaGeneration of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplantGenetic modification of T cellsGeneration of tumor antigen-specific T cell lines from pediatric patients with acute lymphoblastic leukemia--implications for immunotherapy.Adoptive T cell therapy of cancer.Complementation of antigen-presenting cells to generate T lymphocytes with broad target specificity.Summit on cell therapy for cancer: The importance of the interaction of multiple disciplines to advance clinical therapy.Optimizing the production of suspension cells using the G-Rex "M" series.Engineered T cells for pancreatic cancer treatmentGood manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein-Barr virus-associated lymphoma.Supportive care in patients with acute leukaemia: historical perspectives.Adoptive immunotherapy with the use of regulatory T cells and virus-specific T cells derived from cord bloodPiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.Simplified method of the growth of human tumor infiltrating lymphocytes in gas-permeable flasks to numbers needed for patient treatment.A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.Clinical scale rapid expansion of lymphocytes for adoptive cell transfer therapy in the WAVE® bioreactor.Expanding cytotoxic T lymphocytes from umbilical cord blood that target cytomegalovirus, Epstein-Barr virus, and adenovirus.Moving Successful Virus-specific T-cell Therapy for Hematopoietic Stem Cell Recipients to Late Phase Clinical Trials.Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications.The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity.Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease.A single exercise bout enhances the manufacture of viral-specific T-cells from healthy donors: implications for allogeneic adoptive transfer immunotherapyImmunologic special forces: anti-pathogen cytotoxic T-lymphocyte immunotherapy following hematopoietic stem cell transplantation.Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant.CAR-T Cell Therapies From the Transfusion Medicine PerspectiveT cells for viral infections after allogeneic hematopoietic stem cell transplantRandomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma.
P2860
Q26775720-0F7CC5E9-3A05-4C7D-BC26-3687627D8C9DQ26799372-AF6CDC65-667F-4FAF-A78D-B649C07FC1F9Q26801365-600D36D0-306D-481D-BF8A-8799823D8936Q26826830-A0557289-937C-4A07-BB2D-040B0C354B94Q26853345-0BCAF550-9945-4C01-8856-45BE634F0A32Q27024456-021DBF41-3907-4F17-9217-BA6C6BE18E01Q27028006-BC46E8A6-9B85-4225-981D-99EBD13A2343Q28075314-DE860589-20C5-4EDA-83BE-71A355464989Q29393780-B7FF5035-787D-409D-8292-E1A16D828877Q30371742-050EB097-668C-493B-8FF0-28AB35F9F3FAQ30580134-5DB8EBE4-6931-462F-B789-C4B7D1287CB1Q33578792-F7228B83-497A-4B27-A0BE-0F52270904E5Q33633262-EB3FFA54-4DF2-4A3D-A2A6-08157C99E6E2Q34350259-FDB8F91E-3CAD-475D-AA48-29C11DE04B83Q34635978-EFB96362-F404-4FF9-8759-26AA77008434Q34644876-A0AE0A14-DF13-4B8E-AB35-BA3F9DD63FDFQ34803707-61AAB507-3B46-4CAA-B94F-30B908208EF7Q34977470-E37A931B-114B-49CC-9AC0-3BBD6C577812Q35142912-E56CD73A-A1BE-40E6-AED5-A753ABEE5903Q35177618-A2F2E8D6-1FF6-425B-9880-03128ADF20BBQ35184232-ADD68423-A1D0-4B24-9FB8-0819AD3036AEQ35244233-3AFA7BCF-C2AF-4EE1-81C8-4923CC1EC345Q35264185-0F9C3D6F-7B0E-4D15-BF02-9AA9FFA79E54Q35265135-ADDAE28B-3EF5-48AC-9EC6-687B3964CDADQ35582326-F6E92175-DBED-4DE1-8181-B4F1F08896E6Q35623431-6E90ACAE-FEC8-47CA-A9B9-6919672259E0Q35860034-6D5F6B22-BB79-4B9F-88A5-F86274FFC30EQ36062047-072B6C4E-5918-4286-8834-487C6ACFE580Q36110862-F5BE301E-D858-4CC9-A0F3-3C6B6BDB8693Q36305254-9FC9F548-3D13-4AF7-AF3C-D89E513FFBBBQ36438304-9C0A942A-0737-434D-A9A0-F64CEB9747D2Q36676064-B57D3E82-BC50-4C0B-A6ED-CD84864E2051Q36710982-315E7B93-6EA3-4A5C-9CF8-9A3C3B4B6646Q36862468-107C6D40-79E0-4FB1-88B5-BD60A09A84C5Q36903202-D5862DDC-B228-47CE-B0FD-5BEAD9C80410Q36956443-D5F790CE-6771-4C2F-9A0E-564EAC55465DQ36995700-F7B2183E-9D86-4B96-A866-D904E56497BEQ37022738-6B6CDEF8-973D-42C8-840F-11F0B511DD6BQ37058107-D10E4839-2C6A-486A-BEBD-A7301B9E68BEQ37065838-2F5D3264-9380-4893-A190-5D3699EFFE34
P2860
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex).
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Accelerated production of anti ...... expansion cultureware (G-Rex).
@en
Accelerated production of anti ...... le rapid expansion cultureware
@nl
type
label
Accelerated production of anti ...... expansion cultureware (G-Rex).
@en
Accelerated production of anti ...... le rapid expansion cultureware
@nl
prefLabel
Accelerated production of anti ...... expansion cultureware (G-Rex).
@en
Accelerated production of anti ...... le rapid expansion cultureware
@nl
P2093
P2860
P1476
Accelerated production of anti ...... expansion cultureware (G-Rex).
@en
P2093
Ann M Leen
Cliona M Rooney
Gianpietro Dotti
Helen E Heslop
John Wilson
Juan F Vera
Lara J Brenner
Minhtran C Ngo
Ulrike Gerdemann
P2860
P304
P356
10.1097/CJI.0B013E3181C0C3CB
P577
2010-04-01T00:00:00Z